MCID: CLP006
MIFTS: 39

Clopidogrel Resistance malady

Categories: Metabolic diseases

Aliases & Classifications for Clopidogrel Resistance

Aliases & Descriptions for Clopidogrel Resistance:

Name: Clopidogrel Resistance 25
Cyp2c19-Related Poor Drug Metabolism 25
Poor Metabolism of Clopidogrel 25
Resistance to Clopidogrel 25

Classifications:



Summaries for Clopidogrel Resistance

Genetics Home Reference : 25 Clopidogrel resistance is a condition in which the drug clopidogrel is less effective than normal in people who are treated with it. Clopidogrel (also known as Plavix) is an antiplatelet drug, which means that it prevents blood cell fragments called platelets from sticking together (aggregating) and forming blood clots. This drug is typically given to prevent blood clot formation in individuals with a history of stroke; heart attack; a blood clot in the deep veins of the arms or legs (deep vein thrombosis); or plaque buildup (atherosclerosis) in the blood vessels leading from the heart, which are opened by placement of a small thin tube (stent).

MalaCards based summary : Clopidogrel Resistance, also known as cyp2c19-related poor drug metabolism, is related to cyp2c19-related poor drug metabolism and mephenytoin poor metabolizer. An important gene associated with Clopidogrel Resistance is CYP2C19 (Cytochrome P450 Family 2 Subfamily C Member 19), and among its related pathways/superpathways are Cytochrome P450 - arranged by substrate type and Drug metabolism - cytochrome P450. The drugs Aspirin and Pantoprazole have been mentioned in the context of this disorder. Affiliated tissues include heart and testes, and related phenotypes are hematopoietic system and homeostasis/metabolism

Related Diseases for Clopidogrel Resistance

Graphical network of the top 20 diseases related to Clopidogrel Resistance:



Diseases related to Clopidogrel Resistance

Symptoms & Phenotypes for Clopidogrel Resistance

MGI Mouse Phenotypes related to Clopidogrel Resistance:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.81 ITGB3 KDR P2RY1 P2RY12 PTGS2 SELP
2 homeostasis/metabolism MP:0005376 9.7 CYP1A2 HMGCR ITGB3 KDR P2RY1 P2RY12
3 liver/biliary system MP:0005370 9.23 CYP1A2 HMGCR ITGB3 KDR PTGS2 SELP

Drugs & Therapeutics for Clopidogrel Resistance

Drugs for Clopidogrel Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
2
Pantoprazole Approved Phase 4 102625-70-7 4679
3
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1 55142-85-3 5472
4
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
5
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
6
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1 274693-27-5 9871419
7
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
8
Pravastatin Approved Phase 4 81093-37-0 54687
9
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1 73590-58-6 4594
10
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
11
Cilostazol Approved Phase 4 73963-72-1 2754
12
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
13
Ranitidine Approved Phase 4 66357-59-3, 66357-35-5 3001055
14
Tirofiban Approved Phase 4,Phase 1 144494-65-5 60947
15
Phenprocoumon Approved Phase 4 435-97-2 9908 54680692
16
Rivaroxaban Approved Phase 4 366789-02-8
17
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
18
Eptifibatide Approved, Investigational Phase 4 188627-80-7 123610
19
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
20
Prazosin Approved Phase 4 19216-56-9 4893
21
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
22
Amlodipine Approved Phase 4 88150-42-9 2162
23
Indapamide Approved Phase 4 26807-65-8 3702
24
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
25
Bisoprolol Approved Phase 4 66722-44-9 2405
26
Clopidogrel Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 120202-66-6, 113665-84-2 60606
27 Atorvastatin Calcium Phase 4 134523-03-8
28 Rosuvastatin Calcium Phase 4 147098-20-2
29 Prasugrel hydrochloride Phase 4,Phase 3,Phase 2 389574-19-0
30
Proton pump inhibitors Phase 4,Phase 1
31 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
32 Gastrointestinal Agents Phase 4,Phase 1
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
35 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
36 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Antacids Phase 4,Phase 1
39 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
40 Hypolipidemic Agents Phase 4
41 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
42 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Anticholesteremic Agents Phase 4
44 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Purinergic P2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
46 Purinergic P2Y Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
48 Lipid Regulating Agents Phase 4
49 Antimetabolites Phase 4
50 Anti-Ulcer Agents Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 87)
id Name Status NCT ID Phase
1 The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized and Cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction Unknown status NCT02411903 Phase 4
2 Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping ™ Assay Unknown status NCT01023360 Phase 4
3 Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients Unknown status NCT02459288 Phase 4
4 Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel Unknown status NCT01643031 Phase 4
5 Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance Completed NCT00398463 Phase 4
6 Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation Completed NCT01094457 Phase 4
7 Study of Policosanol to Improve Platelet Reactivity After Percutaneous Coronary Stent Implantation (PCI) Completed NCT01371058 Phase 4
8 Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Completed NCT00262561 Phase 4
9 Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention Completed NCT00404781 Phase 4
10 Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects Completed NCT00930670 Phase 4
11 Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting Completed NCT01159639 Phase 4
12 Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI) Completed NCT01463150 Phase 4
13 Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction Completed NCT02026219 Phase 4
14 REsistance to Aspirin and Clopidogrel in acuTe Myocardial Infarction Completed NCT01381185 Phase 4
15 Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment Completed NCT01134380 Phase 4
16 The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment Completed NCT02580149 Phase 4
17 Trial to Assess the Efficacy of Combination Formula of Aspirin Plus Clopidogrel in Patients With Coronary Stent Completed NCT02410083 Phase 4
18 Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel) Completed NCT00728156 Phase 4
19 Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients Completed NCT03114995 Phase 4
20 Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis Completed NCT02215993 Phase 4
21 Aspirin Non-responsiveness and Clopidogrel Endpoint Trial. Completed NCT00222261 Phase 4
22 Antithrombotic Triple Therapy in Humans Completed NCT01812200 Phase 4
23 PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome Completed NCT00296803 Phase 4
24 Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index Completed NCT01502943 Phase 4
25 Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole Recruiting NCT01094275 Phase 4
26 Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Recruiting NCT01261832 Phase 4
27 Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA) Recruiting NCT02539810 Phase 4
28 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Not yet recruiting NCT02698618 Phase 4
29 Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty Terminated NCT00289601 Phase 4
30 Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents Withdrawn NCT00589862 Phase 4
31 Clopidogrel Resistance and Platelet Reactivity in Women Undergoing Percutaneous Coronary Intervention Unknown status NCT01796873 Phase 3
32 Efficacy and Safety Study of Ticagrelor Unknown status NCT01812330 Phase 3
33 ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery Unknown status NCT01046942 Phase 3
34 Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance Unknown status NCT00697021 Phase 3
35 The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance Completed NCT01032668 Phase 3
36 Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI). Completed NCT01109784 Phase 3
37 Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS Completed NCT00444132 Phase 3
38 Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis Completed NCT01155765 Phase 3
39 Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment Completed NCT01304472 Phase 3
40 Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis Completed NCT01511471 Phase 3
41 Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events Completed NCT01586975 Phase 2, Phase 3
42 Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention Completed NCT01360437 Phase 3
43 Low-dose of Ticagrelor and Double Standard-dose Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With Coronary Heart Disease Recruiting NCT03062462 Phase 2, Phase 3
44 Clopidogrel Resistance and Embolism in Carotid Artery Stenting Recruiting NCT02133989 Phase 3
45 Effect of DLBS1033 After Primary PCI in Patients With STE-ACS Recruiting NCT02976701 Phase 2, Phase 3
46 A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion Recruiting NCT02398656 Phase 3
47 A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk Active, not recruiting NCT02044146 Phase 2, Phase 3
48 Clopidogrel Pharmacogenomics Project Completed NCT01097343 Phase 2
49 Retinal Blood Flow and Microthrombi in Type 1 Diabetes Completed NCT00406991 Phase 2
50 TIMES: Ticagrelor vs. Placebo/ Clopidogrel With Aspirin in Anterior STEMI Patients Treated With Primary PCI Recruiting NCT03145194 Phase 2

Search NIH Clinical Center for Clopidogrel Resistance

Genetic Tests for Clopidogrel Resistance

Anatomical Context for Clopidogrel Resistance

MalaCards organs/tissues related to Clopidogrel Resistance:

39
Heart, Testes

Publications for Clopidogrel Resistance

Articles related to Clopidogrel Resistance:

(show all 50)
id Title Authors Year
1
Allele Frequency Distribution of CYP2C19 Genotypes Associated with Clopidogrel Resistance in Russian Population. ( 27673643 )
2016
2
Expression of miRNA-26a in platelets is associated with clopidogrel resistance following coronary stenting. ( 27347088 )
2016
3
Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population. ( 26935114 )
2016
4
Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism. ( 27555873 )
2016
5
A new approach: Left atrial appendage occlusion, as an alternative to anticoagulant, to treat patient who suffered of atrial fibrillation, acute coronary syndrome and clopidogrel resistance. ( 26479956 )
2016
6
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. ( 26961113 )
2016
7
Potent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel Resistance. ( 27594816 )
2016
8
Effects of genetic factors to stent thrombosis due to clopidogrel resistance after coronary stent placement. ( 26828987 )
2016
9
Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? ( 26340464 )
2016
10
Obesity, leptin, and thrombosis: Focus on clopidogrel resistance. ( 27774960 )
2016
11
Effect of obesity and serum leptin level on clopidogrel resistance. ( 27774962 )
2016
12
Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. ( 27133299 )
2016
13
Clopidogrel Resistance in Neurovascular Stenting: Correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate. ( 26272977 )
2015
14
Relation between the Change in Mean Platelet Volume and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Intervention. ( 25322834 )
2015
15
The STIB score: a simple clinical test to predict clopidogrel resistance. ( 26567810 )
2015
16
Clopidogrel Resistance after Minor Ischemic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small-Vessel Disease. ( 26303791 )
2015
17
Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism. ( 25452814 )
2015
18
Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity. ( 26347447 )
2015
19
Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients? ( 25893489 )
2015
20
Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients. ( 26170954 )
2015
21
Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease. ( 26264906 )
2015
22
Tailored antiplatelet therapy in a patient with ITP and clopidogrel resistance. ( 25428265 )
2015
23
Clopidogrel resistance after renal transplantation. ( 25792661 )
2015
24
Association of VEGFR-2 Gene Polymorphisms With Clopidogrel Resistance in Patients With Coronary Heart Disease. ( 25738571 )
2015
25
Clopidogrel resistance: the way forward. ( 25443607 )
2014
26
Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. ( 24996381 )
2014
27
Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population. ( 25112801 )
2014
28
Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients. ( 24745016 )
2014
29
VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. ( 25457586 )
2014
30
Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms. ( 22721490 )
2013
31
Dynamic changes and associated factors of clopidogrel resistance in patients after cerebral infarction. ( 24136585 )
2013
32
Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip capillary electrophoresis. ( 22589111 )
2012
33
Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance. ( 22153531 )
2012
34
Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis. ( 21215696 )
2011
35
Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease. ( 21892403 )
2011
36
[Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis]. ( 21302482 )
2010
37
[Clopidogrel resistance in patients with acute coronary syndrome]. ( 20873239 )
2010
38
Clopidogrel resistance: pharmacokinetic or pharmacogenetic? ( 19246723 )
2009
39
Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease. ( 19667414 )
2009
40
Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. ( 19576320 )
2009
41
Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. ( 18485500 )
2009
42
Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. ( 19660606 )
2009
43
Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. ( 17989373 )
2008
44
The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. ( 18323861 )
2008
45
Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. ( 18387444 )
2008
46
Clopidogrel resistance: role of body mass and concomitant medications. ( 17169448 )
2007
47
Does glycoprotein IIIa gene (Pl(A)) polymorphism influence clopidogrel resistance? : a study in older patients. ( 17432927 )
2007
48
Possible mechanisms of drug-induced aspirin and clopidogrel resistance. ( 17008981 )
2006
49
Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. ( 15634270 )
2005
50
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. ( 14707025 )
2004

Variations for Clopidogrel Resistance

Expression for Clopidogrel Resistance

Search GEO for disease gene expression data for Clopidogrel Resistance.

Pathways for Clopidogrel Resistance

Pathways related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 39)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.18 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
2
Show member pathways
12.65 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
3
Show member pathways
12.22 CYP1A1 CYP1A2 CYP2C19 CYP2J2 CYP3A4
4
Show member pathways
12.17 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 PTGS2
5 12.01 ITGB3 P2RY1 P2RY12 VASP
6 11.97 CYP2C19 CYP2C9 CYP2J2 PTGS2
7
Show member pathways
11.97 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4 PTGS2
8
Show member pathways
11.91 ITGB3 KDR PTGS2
9
Show member pathways
11.84 ABCB1 CYP2C19 CYP2C9 CYP3A4 CYP3A5
10 11.78 ITGB3 KDR PTGS2
11
Show member pathways
11.74 CYP1A1 CYP1A2 CYP3A4
12 11.69 ABCB1 CYP3A4 HMGCR
13
Show member pathways
11.67 CYP1A1 CYP1A2 CYP3A4 CYP3A5
14
Show member pathways
11.63 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
15
Show member pathways
11.57 ABCB1 CYP3A4 CYP3A5
16
Show member pathways
11.55 ABCB1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
17 11.52 CYP1A1 CYP2J2 PTGS2
18 11.49 CYP1A1 CYP1A2 PTGS2
19
Show member pathways
11.47 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
20
Show member pathways
11.41 ABCB1 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4
21 11.38 ABCB1 CYP1A2 CYP2C9 CYP3A4
22
Show member pathways
11.38 ABCB1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
23 11.37 CYP1A1 CYP1A2 CYP2C19
24
Show member pathways
11.33 CYP1A1 CYP1A2 CYP3A4
25 11.31 ABCB1 CYP2C19 CYP2C9 CYP3A4 CYP3A5
26
Show member pathways
11.21 CYP1A2 CYP2C9 CYP3A4
27
Show member pathways
11.21 CYP2C9 CYP2J2 PTGS2
28 11.18 CYP1A1 CYP1A2 CYP2C9 CYP3A4
29 11.13 CYP1A2 CYP3A4 CYP3A5
30
Show member pathways
11.06 ABCB1 CYP3A4
31 11.06 ABCB1 CYP2C9 CYP3A4
32 10.93 ABCB1 CYP3A4 CYP3A5 PTGS2
33 10.93 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5 ITGB3
34 10.9 ABCB1 CYP3A4
35 10.85 ABCB1 CYP3A4 CYP3A5
36 10.78 CYP1A1 CYP1A2
37 10.72 ABCB1 CYP3A4 CYP3A5
38 10.5 CYP2C9 CYP2J2
39 10.34 CYP2C9 CYP3A4

GO Terms for Clopidogrel Resistance

Cellular components related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.96 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
2 endoplasmic reticulum membrane GO:0005789 9.81 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
3 intracellular membrane-bounded organelle GO:0043231 9.61 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
4 lamellipodium membrane GO:0031258 9.43 ITGB3 VASP
5 filopodium membrane GO:0031527 9.4 ITGB3 VASP
6 platelet alpha granule membrane GO:0031092 9.37 ITGB3 SELP
7 organelle membrane GO:0031090 9.23 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
8 membrane GO:0016020 10.22 ABCB1 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2

Biological processes related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 36)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.96 ABCB1 CYP1A1 CYP1A2 PTGS2
2 response to lipopolysaccharide GO:0032496 9.88 CYP1A1 CYP1A2 PTGS2 SELP
3 aging GO:0007568 9.88 CYP1A1 HMGCR P2RY1 PTGS2
4 xenobiotic metabolic process GO:0006805 9.85 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4 CYP3A5
5 response to organic cyclic compound GO:0014070 9.84 CYP1A1 CYP1A2 PTGS2
6 platelet activation GO:0030168 9.83 ITGB3 P2RY1 P2RY12
7 response to organic substance GO:0010033 9.82 CYP1A1 CYP1A2 PTGS2
8 cellular response to organic cyclic compound GO:0071407 9.79 CYP1A1 P2RY1 P2RY12
9 exogenous drug catabolic process GO:0042738 9.76 CYP1A2 CYP2C19 CYP2C9 CYP3A4
10 oxidative demethylation GO:0070989 9.73 CYP1A2 CYP2C9 CYP3A4 CYP3A5
11 omega-hydroxylase P450 pathway GO:0097267 9.71 CYP1A1 CYP1A2 CYP2C19 CYP2C9
12 heterocycle metabolic process GO:0046483 9.69 CYP1A2 CYP2C19 CYP3A4
13 response to immobilization stress GO:0035902 9.67 CYP1A1 CYP1A2
14 lipid hydroxylation GO:0002933 9.67 CYP1A1 CYP3A4 CYP3A5
15 calcium-mediated signaling using intracellular calcium source GO:0035584 9.66 KDR SELP
16 G-protein coupled purinergic nucleotide receptor signaling pathway GO:0035589 9.65 P2RY1 P2RY12
17 cellular response to ATP GO:0071318 9.65 P2RY12 PTGS2
18 cellular response to copper ion GO:0071280 9.64 CYP1A1 CYP1A2
19 glial cell migration GO:0008347 9.63 P2RY1 P2RY12
20 vitamin D metabolic process GO:0042359 9.63 CYP1A1 CYP3A4
21 hydrogen peroxide biosynthetic process GO:0050665 9.62 CYP1A1 CYP1A2
22 drug catabolic process GO:0042737 9.62 CYP1A2 CYP2C9 CYP3A4 CYP3A5
23 adenosine receptor signaling pathway GO:0001973 9.61 P2RY1 P2RY12
24 negative regulation of norepinephrine secretion GO:0010700 9.6 P2RY1 P2RY12
25 positive regulation of ion transport GO:0043270 9.59 P2RY1 P2RY12
26 porphyrin-containing compound metabolic process GO:0006778 9.57 CYP1A1 CYP1A2
27 steroid catabolic process GO:0006706 9.56 CYP1A2 CYP3A4
28 monoterpenoid metabolic process GO:0016098 9.56 CYP1A2 CYP2C19 CYP2C9 CYP3A4
29 dibenzo-p-dioxin metabolic process GO:0018894 9.55 CYP1A1 CYP1A2
30 drug metabolic process GO:0017144 9.55 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4
31 monocarboxylic acid metabolic process GO:0032787 9.54 CYP1A2 CYP2C9
32 alkaloid catabolic process GO:0009822 9.52 CYP3A4 CYP3A5
33 epoxygenase P450 pathway GO:0019373 9.35 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2
34 steroid metabolic process GO:0008202 9.17 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
35 oxidation-reduction process GO:0055114 10.13 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
36 lipid metabolic process GO:0006629 10.02 CYP1A2 CYP2C9 CYP3A4 HMGCR PTGS2

Molecular functions related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.99 CYP1A1 CYP1A2 CYP2C19 CYP3A4 ITGB3 PTGS2
2 iron ion binding GO:0005506 9.95 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
3 aromatase activity GO:0070330 9.77 CYP1A1 CYP1A2 CYP2J2 CYP3A4 CYP3A5
4 steroid hydroxylase activity GO:0008395 9.76 CYP1A1 CYP2C19 CYP2C9 CYP3A4
5 oxygen binding GO:0019825 9.73 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
6 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.72 CYP1A1 CYP1A2 CYP2J2 CYP3A4 CYP3A5
7 arachidonic acid epoxygenase activity GO:0008392 9.7 CYP2C19 CYP2C9 CYP2J2
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.7 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
9 estrogen 16-alpha-hydroxylase activity GO:0101020 9.67 CYP1A1 CYP3A4 CYP3A5
10 caffeine oxidase activity GO:0034875 9.65 CYP1A2 CYP2C9 CYP3A4
11 G-protein coupled purinergic nucleotide receptor activity GO:0045028 9.58 P2RY1 P2RY12
12 demethylase activity GO:0032451 9.58 CYP1A1 CYP1A2
13 (S)-limonene 7-monooxygenase activity GO:0018676 9.57 CYP2C19 CYP2C9
14 (S)-limonene 6-monooxygenase activity GO:0018675 9.56 CYP2C19 CYP2C9
15 heme binding GO:0020037 9.56 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
16 (R)-limonene 6-monooxygenase activity GO:0052741 9.55 CYP2C19 CYP2C9
17 vitamin D 24-hydroxylase activity GO:0070576 9.54 CYP1A1 CYP3A4
18 monooxygenase activity GO:0004497 9.17 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
19 oxidoreductase activity GO:0016491 10.09 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4

Sources for Clopidogrel Resistance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....